PEPSCOPE develops and provides advanced customer-focused protein analysis services and products. We aim to make kinase inhibitors better therapeutics by giving unique insights into their functioning, through quantitative profiling of kinase activities in tissues. We want to accelerate drug development by providing pharmaceutical companies and academic researchers with crucial knowledge about in vivo effects of compounds on the kinome, leading to more efficacious therapies for targeted patient groups.
We continuously advance our capabilities in mass spectrometry and kinome profiling technologies through our valued collaborations with the Utrecht University – Department of Maarten Altelaar & Albert Heck, the Erasmus Medical Center in Rotterdam – Departments of Theo Luider (Neurology), Sieger Leenstra (Neurosurgery), Maikel Peppelenbosch (MDL) – and industry partners.
We offer unique comprehensiveness and data quality for the analysis of cells and tissues. Our primary customers are in the pharma and research segments focussing on cancer and drug research and monitoring response to therapies.
Protein kinase profiling technologies
>10 years experience with high-end LC-MS
>15 years experience with kinome profiling technologies
Chief Executive Officer, co-founder
Anna is a pragmatic leader and team player with longstanding experience in proteomics. She joined Pepscope in 2018 as Scientific Lead in mass spectrometry, bringing over eight years of experience in academic and industrial R&D, including Nerviano Medical Sciences. In 2018, Anna took the initiative for a strategic partnership between Pepscope and Utrecht University, resulting in the adoption of QuantaKinome technology. She has led the Pepscope team since 2019, culminating in accepting a position as CEO in 2020. This appointment coincided with the completion of a successful investment of €4.3 million, in which she played a crucial role. Anna obtained her Ph.D. at the Utrecht University in the Biomolecular Mass Spectrometry & Proteomics group, has a cum laude M.Sc. in Chemistry from the University of Bologna, and a degree in Cancer Pharmacology from the University of Milan.
Ron van Eijsden
Business Development Director
Ron joined Pepscope in 2021 as Business Development Director. With over 25 years of professional experience, he has been involved in various companies including Kreatech Diagnostics (now part of Leica Biosystems), DOCS/ICON, DCPrime, WCCT/Medelis, Catalyst Clinical Research, HALIX and HAL Allergy. Ron brings a broad commercial experience in life sciences covering multiple fields like research, product - & drug development, manufacturing, medical devices, quality, clinical research, and throughout his carrier he has always been involved in business development. Ron holds a Ph.D. in Molecular Biology from Leiden University, where he studied the mutational analysis of pea lectin.
Head of Biology
Nynke joined Pepscope in 2018 as a biological scientist with expertise in kinase phosphorylation in the field of immunology and transplantation. Nynke studied Biopharmaceutical Sciences at Leiden University and obtained her master’s degree in 2013. In 2018, she completed her doctoral training within the Rotterdam Transplant Group of the Erasmus Medical Center. During her Ph.D. project, she investigated new pharmacodynamic assays for monitoring signaling pathways after transplantation, assessing the phosphorylation status of protein kinases in immune cells.
Erik de Graaf
Head of Technology
Erik joined Pepscope in 2019 as senior scientist experienced in proteomics techniques, clinical lab automation and molecular characterization of human cancer. Erik obtained his Ph.D. in the Biomolecular Mass Spectrometry & Proteomics group at Utrecht University where he mastered advanced and state-of-the-art MS-based proteomics techniques to study protein phosphorylation in aging and cancer. Erik worked for two years at the Fondazione Pisana per la Scienza in Italy where he led the development and automation of MS assays for proteomics analysis in clinical tissues. Since 2016, Erik worked at Sanquin Research where he applied his knowledge to investigate human antibodies.
Giulia De Sabbata
Giulia joined Pepscope in 2020 as scientist experienced in molecular biology and proteomics technologies. She obtained her Ph.D. in Life and Molecular Sciences at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Italy. During her studies, she focused on developing novel proteomics workflows using immunoprecipitation coupled to mass spectrometry to study protein-protein interaction pathways and their perturbation in diseases. Previously, Giulia took part in a multi-laboratory collaboration project with Selecta Biosciences and Genethon where she contributed to pre-clinical development of a new AAV-based gene therapy for treatment of OTC deficiency.
Sidrah joined Pepscope in 2017 with experience in protein characterization and quality control. She is currently responsible for overseeing the daily laboratory operations at Pepscope. She studied Biology and Medical Laboratory Research, followed by a Master’s degree in Biomedical Sciences at Leiden University in 2014. Sidrah worked at the quality control department at Jansen Biologics, followed by HAL Allergy in 2016, where she focused on method development for protein quantification and protein characterization.
Annejet Morris – Gülcher
Annejet joined Pepscope in 2021 with experience in setting up office administrative processes. After working more than ten years in several industries across South Africa and Europe, Annejet joined Sue Ryder as Online Shop Team Lead in 2014. There she was responsible for setting up procedures, improving customer service, and increasing the overall feedback scores on the selling platforms. She completed an ILM-approved Management Development program in 2016. In 2019, Annejet joined Basecone, an IT scale-up in the Netherlands, where she was responsible for office management and an office refurbishment project.
Board Member, co-founder
Hans studied Applied Physics at Delft University of Technology, graduating (Ir.) in 1982. After working for Philips, ASMI NV and European Silicon Structures Ltd, a high tech semiconductor company, he started his first business, CPS Europe, developing electronic products in 1993. He is a co-founder of Pepscope, founder of Omniradar and Optics11 and holds several patents.
Chairman of the Board, co-founder
Jos is a biotech entrepreneur with over 20 years of executive level bio-business experience in companies including Mimetas, Pepscan, SkylineDx, Kreatech Diagnostics (now part of Leica Biosystems ) and Westburg. He is a co-founder of Pepscope and CEO and co-founder of Mimetas. As a scientist, he studied vertebrate embryonal axis formation and brain development at the Hubrecht Institute (Utrecht, NL) and King’s College (London, UK). He has published over 50 scientific papers and patents. Jos holds a cum laude master’s degree in business marketing, a master’s degree in biology and a Ph.D. in developmental biology.
Maarten is associate professor at the Department of Pharmaceutical Sciences of the Utrecht University and head of the proteomics facility at The Netherlands Cancer Institute (NKI). His research focuses on the development and implementation of innovative mass spectrometric methods for the characterization of proteins, protein complexes and their post-translational modifications in relation to their biological function in health and disease. He has published over 90 scientific papers. Maarten received a prestigious VIDI grant in 2013, is a partner in large research consortia such as X-Omics.nl and Epic-XS and is currently the treasurer of the Dutch Society for Mass Spectrometry (NVMS), and the International Mass Spectrometry Foundation (IMSF).